Patent Issues
The patents for the Rythmol family of products are owned by Reliant Pharmaceuticals, Inc., in Liberty Corner, N.J. Reliant acquired the patents from developer Abbott Laboratories, Inc., in 2003. Rythomol was originally developed in Europe and marketed by Knoll Pharma both in Europe and North America. The product was taken over by Abbott in 2001 when Abbott purchased Knoll.
Reliant Pharmaceuticals filed a federal patent infringement lawsuit against generic drug maker Par Pharmaceuticals, Inc., on December 19, 2006. The lawsuit, filed in the federal district court for Delaware, seeks to prevent Par from manufacturing a generic version of Rythmol. Par is seeking approval to do so from the U.S. Food and Drug Administration.
Reliant's patent for the drug was issued in October, 1997, and it expires in 2014. Par believes the patent is invalid, according to its filing with the FDA.
Read more about this topic: Propafenone
Famous quotes containing the words patent and/or issues:
“This is the patent age of new inventions
For killing bodies, and for saving souls,
All propagated with the best intentions.”
—George Gordon Noel Byron (1788–1824)
“The “universal moments” of child rearing are in fact nothing less than a confrontation with the most basic problems of living in society: a facing through one’s children of all the conflicts inherent in human relationships, a clarification of issues that were unresolved in one’s own growing up. The experience of child rearing not only can strengthen one as an individual but also presents the opportunity to shape human relationships of the future.”
—Elaine Heffner (20th century)